MPM Bioimpact LLC Has $12.81 Million Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)

MPM Bioimpact LLC lifted its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) by 17.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 460,617 shares of the company’s stock after acquiring an additional 68,073 shares during the period. Akero Therapeutics makes up about 1.8% of MPM Bioimpact LLC’s portfolio, making the stock its 24th largest holding. MPM Bioimpact LLC’s holdings in Akero Therapeutics were worth $12,814,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in AKRO. Sterling Capital Management LLC increased its position in Akero Therapeutics by 764.3% in the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock valued at $50,000 after acquiring an additional 1,582 shares during the period. Quarry LP acquired a new stake in shares of Akero Therapeutics during the fourth quarter worth $83,000. Summit Investment Advisors Inc. grew its holdings in Akero Therapeutics by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock worth $197,000 after purchasing an additional 450 shares during the period. Hsbc Holdings PLC grew its holdings in Akero Therapeutics by 8.5% in the fourth quarter. Hsbc Holdings PLC now owns 7,886 shares of the company’s stock worth $220,000 after purchasing an additional 621 shares during the period. Finally, AlphaQuest LLC lifted its stake in shares of Akero Therapeutics by 32,588.0% in the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company’s stock valued at $227,000 after buying an additional 8,147 shares in the last quarter.

Akero Therapeutics Trading Down 3.7%

Shares of AKRO opened at $40.01 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a 1 year low of $17.86 and a 1 year high of $58.40. The company has a 50 day simple moving average of $41.07 and a two-hundred day simple moving average of $37.66. The firm has a market cap of $3.19 billion, a P/E ratio of -10.67 and a beta of -0.12.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings data on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of ($1.01) by $1.91. On average, equities analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on AKRO shares. HC Wainwright raised their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, March 3rd. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. Citigroup reduced their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Tuesday. Canaccord Genuity Group increased their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Finally, UBS Group boosted their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $76.00.

Insider Buying and Selling

In other Akero Therapeutics news, VP Patrick Lamy sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $48.09, for a total value of $48,090.00. Following the sale, the vice president now owns 33,492 shares in the company, valued at approximately $1,610,630.28. This represents a 2.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director G. Walmsley Graham bought 91,309 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The shares were acquired at an average price of $44.75 per share, for a total transaction of $4,086,077.75. Following the transaction, the director now directly owns 1,091,309 shares in the company, valued at approximately $48,836,077.75. This represents a 9.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 219,208 shares of company stock valued at $9,218,994 over the last three months. 7.94% of the stock is owned by company insiders.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.